PRZOOM - /newswire/ -
Washington, DC, United States, 2012/03/22 - The American Pharmacists Association (APhA) presented testimony to the Food and Drug Association at the public hearing Using Innovative Technologies and other Conditions of Safe Use to Expand Which Drug Products Can Be Considered Nonprescription.
APhA today presented testimony to the Food and Drug Association (FDA) at the public hearing Using Innovative Technologies and other Conditions of Safe Use to Expand Which Drug Products Can Be Considered Nonprescription. At this hearing, the FDA is receiving input as it considers ways to make the distinction between prescription and nonprescription drugs less rigid; increasing patients access to needed medications under “conditions of safe use.” An example of a safe-use condition would be requiring an interaction with a pharmacist before the purchase of the medicine.
APhA presented testimony regarding the impact of this potential drug paradigm on pharmacists, patient access to pharmacists and the many opportunities pharmacists have to speak with patients with chronic conditions - treated and untreated - helping to channel those patients back into the health care system. APhA’s comments were presented by Thomas E. Menighan, BSPharm, MBA, ScD, FAPhA, APhA Executive Vice President and CEO.
APhA’s comments were based upon the following:
• Support for the concept of “conditions of safe use” for certain medications, which could include a consultation with a pharmacist.
• The opportunity to expand patient access, improve public health and provide another avenue to bring people who may have poorly treated chronic conditions back into the health care system.
• The opportunity to further communicate and collaborate with physicians and other providers.
• The success of pharmacist-administered immunizations and other patient care programs on improving public health. And,
• A recognition that there are several key focus areas to be resolved as the potential drug paradigm concept evolves.
Menighan commented,“While many details of this potential drug paradigm need to be worked out through future collaborations, none of them are significant enough to stop this important initiative from being enacted. America's pharmacists view this proposal as ‘Yes... if, ’ rather than ‘No... but.’ We look forward to working with FDA and other healthcare providers and stakeholders to answer the ‘if’ questions and make this concept a reality for the benefit of patients and the healthcare system.”
APhA’s complete testimony to the FDA can be found in the APhA Newsroom at pharmacist.com/newsroom.
About the American Pharmacists Association
The American Pharmacists Association (aphanet.org / pharmacist.com), founded in 1852 as the American Pharmaceutical Association, is a 501 ©(6) organization, representing more than 62,000 practicing pharmacists, pharmaceutical scientists, student pharmacists, pharmacy technicians and others interested in advancing the profession. APhA, dedicated to helping all pharmacists improve medication use and advance patient care, is the first-established and largest association of pharmacists in the United States.